10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
New trial evaluates ripretinib vs sunitinib in advanced GIST patients with specific KIT mutations
Phase 2 trial finds ripretinib effective and safer than sunitinib for advanced GIST in Chinese patients.